Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2086130 | 1.00 | USP2 (0.43) | USP2SMN1; SMN2CTSKCHRM2CHRM4 | |
| SCHEMBL1498893 | 1.00 | USP2 (0.43) | USP2SMN1; SMN2CTSKCHRM2CHRM4 | |
| SCHEMBL26430057 | 0.82 | USP2 (0.47) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL30418583 | 0.80 | USP2 (0.43) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL17532546 | 0.79 | USP2 (0.45) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL14165640 | 0.79 | USP2 (0.45) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL14604907 | 0.79 | USP2 (0.45) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL14165639 | 0.79 | USP2 (0.45) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL1498807 | 0.79 | GPR119 (0.44) | USP2SMN1; SMN2CTSKALDH1A1MEN1 | |
| SCHEMBL2085183 | 0.79 | GPR119 (0.44) | USP2SMN1; SMN2CTSKALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210069193-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION | 2021-03-11 | — | — | US | disclosed |
| US-20190111058-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION | 2019-04-18 | — | — | US | disclosed |
| US-9249145-B2 | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150246046-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION | 2015-09-03 | — | — | US | disclosed |
| WO-2011028685-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111058-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | JAK1, JAK2, JAK3 | USP2 1573/4885SMN1; SMN2 2529/4885CTSK 3806/4885 |
| US-20150246046-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | JAK1, JAK2, JAK3 | USP2 1573/4885SMN1; SMN2 2529/4885CTSK 3806/4885 |
| US-20210069193-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | JAK1, JAK2, JAK3 | USP2 1573/4885SMN1; SMN2 2529/4885CTSK 3806/4885 |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | USP2 2953/4885SMN1; SMN2 4287/4885CTSK 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.